The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
Cancer Treat Rev
; 74: 29-34, 2019 Mar.
Article
en En
| MEDLINE
| ID: mdl-30708267
ABSTRACT
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias de la Mama
/
Antineoplásicos Hormonales
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Año:
2019
Tipo del documento:
Article
País de afiliación:
Suiza